NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. We view the immune system holistically and, rather than target one specific immune cell type, we focus on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. Through our proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology, or FIND-IO, platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. We are focused on patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies.
Location: United States, Maryland, Beltsville
Employees: 51-200
Total raised: $160M
Founded date: 2015
Investors 8
Funding Rounds 2
| Date | Series | Amount | Investors |
| 13.11.2018 | Series B | $93M | - |
| 06.01.2016 | Series A | $67M | - |
Mentions in press and media 12
| Date | Title | Description |
| 05.03.2024 | NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances | - |
| 04.10.2022 | ROTH Capital Partners to Host Inaugural Healthcare Opportunities Conference on October 6th at the Yale Club in New York City | Event to feature company presentations and one-on-one meetings between institutional investors and senior management from select Healthcare companies in Biotechnology, Pharmaceuticals, Medical Technologies, Oncology and Mental Health Therap... |
| 19.10.2021 | NextCure : Announces Three New Members of its Scientific Advisory Board | BELTSVILLE, Md., Oct. 19, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-rela... |
| 04.10.2021 | NextCure : Announces New Appointments to its Board of Directors (Form 8-K) | NextCure Announces New Appointments to its Board of Directors BELTSVILLE, Md., October 4, 2021 - NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunom... |
| 04.10.2021 | NextCure : Announces New Appointments to its Board of Directors | BELTSVILLE, Md., Oct. 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-rela... |
| 09.05.2019 | Four biotech companies announce pricings of IPOs, looking to raise more than $300M | NextCure, based in Beltsville, Maryland, said Wednesday that it had priced its IPO of 5 million shares at $15 each. Montreal-based Milestone said it had priced its 5.5 million share IPO also at $15 per share. Cortexyme, based in South San F... |
| 13.11.2018 | NextCure Nabs $93M Series B Funding | BELTSVILLE, MD, NextCure today announced the completion of a $93 million series B equity financing. >> Click here for more funding data on NextCure >> To export NextCure funding data to PDF and Excel, click here NextCure,... |
| 13.11.2018 | NextCure Raises $93M In Series B Financing | BELTSVILLE, Md.--(BUSINESS WIRE)--NextCure Inc., a privately-held biopharmaceutical company discovering and developing the next generation of immunomedicines for cancer and other diseases, today announced the completion of a $93 million ser... |
| 13.11.2018 | NextCure Completes a $93M Series B Financing | - |
| 06.01.2016 | NextCure Announces $67M in Series A | announced that it has raised a $67 million Series A financing. >> Click here for more funding data on NextCure >> To export NextCure funding data to PDF and Excel, click here GERMANTOWN, Md. and NEW HAVEN, NextCure, Inc.,... |
Show more